Pharmaceutical company Celgene has participated in a $23m series A round for US-based clinical stage biopharmaceutical company Aadi Bioscience.

The round was led by healthcare-focused private equity firm Hermed Capital and also featured Vivo Capital, Decheng Capital, Star Summit Ventures and Helsinn Investment Fund.

Aadi Bioscience is working on a drug candidate dubbed ABI-009 which it licensed from Celgene in 2014 in order to target various cancer indications and cardiovascular diseases.

The series A capital will support a phase…